Cell and Gene Therapy Catapult
Innovate UK-backed advanced therapies catapult now making seed investments; first deal was Spliceor
- Government & grants
- London
- Type
- Government & grants
- Based in
- London
- Stages
- Pre-seed, Seed
- Sector focus
- Biotech & Life Sciences, Healthtech
- Fund size
- Undisclosed
- Founded
- 2012
- Website
- ct.catapult.org.uk
The Cell and Gene Therapy Catapult is a not-for-profit innovation centre established in 2012 within the Innovate UK Catapult Network to grow the UK's advanced therapies industry. Headquartered in London, it provides research, manufacturing and commercialisation support for cell and gene therapy developers. Under the Innovate UK-supported Cross-Catapult Investment Pilot it now makes seed investments in early-stage advanced therapy companies, assessed by a dedicated investment committee of therapy and venture specialists. Its first investment under the pilot, in 2025, went to Spliceor, a University of Cambridge spin-out developing a trans-splicing gene therapy platform with an initial focus on liver cancer.
Team
- Matthew Durdy, Chief Executive
- Jim Faulkner, Chairman
Portfolio in the directory
← All investors · Is this your organisation? Request an update
More investors in the directory
Octopus Ventures
London VC arm of Octopus Investments backing founders from pre-seed to growth; backed ManyPets
M&G Investments
Asset management arm of M&G plc; its Catalyst strategy joined PhysicsX's $300m Series C in 2026
Kadmos Capital
London deep-tech and impact VC investing across AI & data, techbio and sustainability; backed DEScycle
Green Angel Ventures
London climate-tech angel syndicate and EIS fund; backed DEScycle, NatureMetrics and Qflow
White Star Capital
Global multi-stage tech VC with London and New York roots; backed Numan and MyEdSpace
The Francis Crick Institute (KQ Labs)
KQ Labs, the Crick's data-driven biomedical accelerator; backed LinkGevity
Subscribe to Newsletter
UK startup news, founder stories and funding insight, straight to your inbox every week. Free.